SCHEMBL9685093

SCHEMBL9685093

Cc1ccc(C(C)C)cc1CO

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.55
TRPA1 O75762 1/20 0.55
CACNA1C Q13936 1/20 0.55
LMNA P02545 1/20 0.52
S1PR1 P21453 1/20 0.49
ACHE P22303 8/20 0.41
BCHE P06276 6/20 0.41
HTT P42858 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
ALOX12 P18054 1/20 0.39
HIF1A Q16665 1/20 0.39
SHBG P04278 1/20 0.38
PTGS2 P35354 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
RNASEH1 O60930 1/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11443445 0.84 PTGS1 (0.52) PTGS1TRPA1CACNA1CLMNAS1PR1
SCHEMBL1762784 0.83 LMNA (0.52) PTGS1TRPA1CACNA1CLMNAS1PR1
SCHEMBL10053119 0.83 PTGS1 (0.50) PTGS1TRPA1CACNA1CLMNAS1PR1
SCHEMBL11981072 0.83 TRPA1 (0.43) PTGS1TRPA1CACNA1CLMNAHTT
SCHEMBL16263301 0.82 S1PR1 (0.49) PTGS1TRPA1CACNA1CS1PR1ACHE
SCHEMBL11443444 0.81 PTGS1 (0.48) PTGS1TRPA1CACNA1CLMNAS1PR1
SCHEMBL11449732 0.81 LMNA (0.54) PTGS1TRPA1CACNA1CLMNAS1PR1
SCHEMBL18713552 0.80 S1PR1 (0.47) PTGS1TRPA1CACNA1CLMNAS1PR1
SCHEMBL10215349 0.79 ADRB2 (0.54) PTGS1TRPA1CACNA1CLMNAHTT
SCHEMBL14227856 0.79 LMNA (0.52) PTGS1TRPA1CACNA1CLMNAS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3041842-B1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS KAROS PHARMACEUTICALS INC (US) 2019-10-23 EP disclosed
US-9199959-B2 HIV replication inhibitor SHIONOGI & CO., LTD. (JP) 2015-12-01 US disclosed
US-20140249306-A1 HIV REPLICATION INHIBITOR SHIONOGI & CO., LTD. (JP) 2014-09-04 US disclosed
US-5122442-A Water soluble binder; photosensitive compound HOECHST CELANESE CORPORATION (US) 1992-06-16 US disclosed
US-4436804-A Light-sensitive polymeric diazonium condensates and reproduction compositions and materials therewith AMERICAN HOECHST CORPORATION (US) 1984-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249306-A1 HIV REPLICATION INHIBITOR SSU72, RTF2, ZC3HAV1 PTGS1 3702/4885TRPA1 4835/4885CACNA1C 3080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.